Drug Trial Radar · NCT00972283
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Apr 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,006
Actual
Start
Sep 1, 2009
Primary completion
Oct 28, 2010
Study completion Oct 28, 2010
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp) with/without metformin and with/without pioglitazone in subjects with type 2 diabetes (main period) followed by investigating the long-term safety in terms of comparing NN1250 with insulin glargine plus insulin aspart with or without metformin and with or without pioglitazone in subjects with type 2 diabetes. All oral anti-diabetic drug (OAD) treatment will be discontinued, if applicable, when trial participant enters the trial (NN1250-3582) with the exception of metformin and pioglitazone. Subjects who consent to participate in the extension trial (NN1250-3667) will continue to receive the treatment to which they were randomly allocated in the 52 week trial NN1250-3582. The main period is registered internally at Novo Nordisk as NN1250-3582 while the extension period is registered as NN1250-3667.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
insulin degludecDrug
Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
insulin glargineDrug
Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
insulin aspartDrug
Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of TreatmentTime frame: Week 0, Week 52
- Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic EpisodesTime frame: Week 0 to Week 78 + 7 days follow up
- Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic EpisodesTime frame: Week 0 to Week 78 + 7 days follow up
- Rate of Treatment Emergent Adverse Events (AEs)Time frame: Week 0 to Week 78 + 7 days follow up
Locations
136 sites in 12 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Alexander City, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Goodyear, Arizona
Novo Nordisk Investigational Site
Peoria, Arizona
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Huntington Beach, California
Novo Nordisk Investigational Site
Los Gatos, California
Novo Nordisk Investigational Site
Salinas, California
Novo Nordisk Investigational Site
Santa Monica, California
Novo Nordisk Investigational Site
Spring Valley, California
Novo Nordisk Investigational Site
Tustin, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Milford, Connecticut
Novo Nordisk Investigational Site
Norwalk, Connecticut
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Washington D.C., District of Columbia
Novo Nordisk Investigational Site
Gainesville, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Lake Mary, Florida
Novo Nordisk Investigational Site
Orlando, Florida
Novo Nordisk Investigational Site
Plantation, Florida
Novo Nordisk Investigational Site
West Palm Beach, Florida
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Fort Valley, Georgia
Novo Nordisk Investigational Site
Honolulu, Hawaii
Novo Nordisk Investigational Site
Nampa, Idaho
Novo Nordisk Investigational Site
Evansville, Indiana
Novo Nordisk Investigational Site
Indianapolis, Indiana
Novo Nordisk Investigational Site
New Albany, Indiana
Novo Nordisk Investigational Site
Metairie, Louisiana
Novo Nordisk Investigational Site
Metairie, Louisiana
Novo Nordisk Investigational Site
Hyattsville, Maryland
Novo Nordisk Investigational Site
North East, Maryland
Novo Nordisk Investigational Site
Rockville, Maryland
Novo Nordisk Investigational Site
Eagan, Minnesota
Novo Nordisk Investigational Site
Jefferson City, Missouri
Novo Nordisk Investigational Site
St Louis, Missouri
Novo Nordisk Investigational Site
Lincoln, Nebraska
Novo Nordisk Investigational Site
Omaha, Nebraska
Novo Nordisk Investigational Site
Las Vegas, Nevada
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.